非注射胰島素市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、配銷通路、地區和競爭細分，2020-2030 年）

2024 年全球非注射胰島素市值為 31.4 億美元，預計到 2030 年將達到 54.5 億美元，預測期內複合年成長率為 9.63%。該市場涵蓋無需針頭注射的胰島素製劑，為傳統的注射給藥提供替代方案。目前正在開發非注射胰島素選項（例如口服藥丸、吸入劑、噴霧劑和貼片），以提高患者的依從性和生活品質，特別是對於那些面臨注射困難的患者。這些輸送系統旨在提供更方便用戶使用的體驗，同時保持有效的血糖控制。儘管前景光明，但由於臨床上的挫折，市場仍面臨障礙；例如，Oramed Pharmaceuticals 的口服胰島素候選藥物 ORMD-0801 未能達到其主要終點，而 Biocon 則停止了 Tregopil 治療 1 型糖尿病的 1 期試驗。然而，隨著持續創新和以患者為中心的產品開發，非注射胰島素療法有望成為糖尿病管理的可行替代方案。

關鍵市場促進因素

改善血糖控制

主要市場挑戰

功效和安全問題

主要市場趨勢

個人化治療方法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球非注射胰島素市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（藥丸、噴霧等）
  • 依配銷通路（醫院藥局、網路藥局、藥局）
  • 按地區（北美、歐洲、亞太、南美、中東和非洲）
  • 按公司分類（2024）
• 市場地圖
  • 按產品
  • 按配銷通路
  • 按地區

第6章：北美非注射胰島素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲非注射胰島素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太非注射胰島素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲非注射胰島素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲非注射胰島素市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球非注射胰島素市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Midatech Pharma Plc
• Shreya Life Sciences Pvt. Ltd.
• Boston Therapeutics, Inc.
• Coromed, Inc.
• Diabetology Ltd.
• Emisphere Technologies, Inc.
• Oramed Pharmaceuticals, Inc.
• Diasome Pharmaceuticals, Inc.
• Generex Biotechnology Corp.
• Biodel, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

The Global Non-Injectable Insulin Market was valued at USD 3.14 Billion in 2024 and is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 9.63% during the forecast period. This market encompasses insulin formulations designed to be administered without needles, offering alternatives to traditional injection-based delivery. Non-injectable insulin options-such as oral pills, inhalable forms, sprays, and patches-are being developed to improve patient adherence and quality of life, especially for individuals who face challenges with injections. These delivery systems aim to offer a more user-friendly experience while maintaining effective blood glucose control. Despite the promise, the market faces hurdles due to clinical setbacks; for instance, Oramed Pharmaceuticals' oral insulin candidate ORMD-0801 failed to meet its primary endpoint, and Biocon halted a Phase 1 trial of Tregopil for Type 1 diabetes. However, with continued innovation and patient-centric product development, non-injectable insulin therapies are expected to gain traction as a viable alternative for diabetes management.

Key Market Drivers

Improved Glycemic Control

Enhanced glycemic control is a pivotal driver of growth in the Global Non-Injectable Insulin Market. Traditional injectable insulin can be uncomfortable, often leading to poor compliance. Non-injectable delivery systems address this by offering less invasive options, improving patient adherence and reducing anxiety associated with needle use. These alternatives also support earlier initiation of insulin therapy, allowing better management of blood glucose levels and delaying the progression of diabetes-related complications. By accommodating patients with physical limitations or needle aversion, these technologies increase treatment accessibility and improve health outcomes. The availability of user-friendly insulin forms also encourages adoption among previously reluctant patient populations, thereby expanding the market base and accelerating growth.

Key Market Challenges

Efficacy and Safety Concerns

Concerns over the effectiveness and safety of non-injectable insulin continue to hinder broader market adoption. While these alternatives promise improved convenience, they must demonstrate clinical efficacy equivalent to traditional injections to gain widespread acceptance. Issues such as variable absorption rates and inconsistent glucose control can create doubts among healthcare professionals. Furthermore, the potential for unknown long-term side effects associated with newer delivery technologies adds to skepticism. Regulatory bodies require robust evidence to approve such therapies, and without it, product launches may be delayed or restricted. This uncertainty affects physician confidence and limits patient uptake, ultimately restraining market expansion.

Key Market Trends

Personalized Treatment Approaches

The growing trend toward personalized medicine is significantly shaping the Global Non-Injectable Insulin Market. Tailoring treatment strategies to individual patient needs-considering factors like lifestyle, age, comorbidities, and psychological preferences-enhances therapy adherence and outcomes. Non-injectable insulin options provide flexibility that supports this personalization. For instance, oral formulations may better suit elderly patients with dexterity issues, while sprays may appeal to younger demographics seeking ease and discretion. Customized treatment protocols that incorporate these delivery systems can minimize patient discomfort and improve disease management. This trend aligns with the broader healthcare movement toward patient-centered care and is expected to contribute significantly to the market's long-term growth.

Key Market Players

• Midatech Pharma Plc
• Shreya Life Sciences Pvt. Ltd.
• Boston Therapeutics, Inc.
• Coromed, Inc.
• Diabetology Ltd.
• Emisphere Technologies, Inc.
• Oramed Pharmaceuticals, Inc.
• Diasome Pharmaceuticals, Inc.
• Generex Biotechnology Corp.
• Biodel, Inc.

Report Scope:

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Injectable Insulin Market, By Product:

• Pills
• Sprays
• Others

Non-Injectable Insulin Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Drug Stores

Non-Injectable Insulin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Injectable Insulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Pills, Sprays, and Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Non-Injectable Insulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Injectable Insulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Non-Injectable Insulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Non-Injectable Insulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Non-Injectable Insulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Non-Injectable Insulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Non-Injectable Insulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Non-Injectable Insulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Non-Injectable Insulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Non-Injectable Insulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-Injectable Insulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Non-Injectable Insulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Non-Injectable Insulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Non-Injectable Insulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Non-Injectable Insulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. South America Non-Injectable Insulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-Injectable Insulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Non-Injectable Insulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Non-Injectable Insulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Non-Injectable Insulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-Injectable Insulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Non-Injectable Insulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Non-Injectable Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Midatech Pharma Plc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel Details
  • 15.1.6. SWOT Analysis
• 15.2. Shreya Life Sciences Pvt. Ltd.
• 15.3. Boston Therapeutics, Inc.
• 15.4. Coromed, Inc.
• 15.5. Diabetology Ltd.
• 15.6. Emisphere Technologies, Inc.
• 15.7. Oramed Pharmaceuticals, Inc.
• 15.8. Diasome Pharmaceuticals, Inc.
• 15.9. Generex Biotechnology Corp.
• 15.10. Biodel, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer